Meta-Analysis of ABCB1 3435C>T polymorphism and colorectal cancer

Pakistan Journal of Medical Sciences

Volumn 29, Issue 5, 2013, Pages

  Zhang, Dan ^a   Wang, Cun ^a   Zhou, Zongguang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

ABCB1; Colorectal cancer; MDR1; Meta analysis; P gp; Polymorphism

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

ASIAN; CANCER RISK; CAUCASIAN; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; META ANALYSIS; POLYMERASE CHAIN REACTION; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84881516860     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.295.3758     Document Type: Review

References (42)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Gross CP, McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, Tinetti ME. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med. 2006;145:646-653.
3. Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol. 2003;14:128-149.
4. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci. 2000;25:1-6.
5. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA. 1987;84:265-269.
6. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 1991;51:2720-2726.
7. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ. Pharmacogenetics of Membrane Transporters Investigators Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003;13:481-494.
8. Hoffmeyer S, Burk O, Von RO, Arnold HP, Brockmoller J, Johne A. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473-3478.
9. Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F, Andriulli A. Multidrug resistance 1 gene in inflammatory bowel disease: A meta-analysis. World J Gastroenterol. 2006;12:3636-3644.
10. Lu PH, Wei MX, Yang J, Liu X, Tao GQ, Shen W. Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat. 2011;125:537-543.
11. Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, Bialecka M, Gornik W. Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol. 2005;61:389-394.
12. Sainz J, Rudolph A, Hein R, Hoffmeister M, Buch S, von Schonfels W. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1 and SHBG genes with colorectal cancer risk. Endocr Relat Cancer. 2011;18:265-276.
13. Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009;9:407.
14. Osswald E, Johne A, Laschinski G, Arjomand-Nahad F, Malzahn U, Kirchheiner J. Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur J Clin Pharmacol. 2007;63:9-16.
15. Panczyk M, Balcerczak E, Piaskowski S, Jamroziak K, Pasz-Walczak G, Mirowski M. ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. Int J Colorectal Dis. 2009;24:895-905.
16. Bae SY, Choi SK, Kim KR, Park CS, Lee SK, Roh HK. Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci. 2006;97:774-779.
17. Petrova DT, Nedeva P, Maslyankov S, Toshev S, Yaramov N, Atanasova S. No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol. 2008;134:317-322.
18. De Iudicibus S, De Pellegrin A, Stocco G, Bartoli F, Bussani R, Decorti G. ABCB1 Gene Polymorphisms and Expression of P-glycoproteinand Long-term Prognosis in Colorectal Cancer. Anticancer Research. 2008;28:3921-3928.
19. Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004;72:314-321.
20. Gervasini G, Carrillo JA, Garcia M, San JC, Cabanillas A, Benitez J. Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. Cancer. 2006;107:2850-2857.
21. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987;84:7735-7738.
22. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. Relevance of p-glycoprotein for the enteral absorption of cyclosporine A: in vitro-in vivo correlation. Br J Pharmacol. 1996;118:1841-1847.
23. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol. 2003;58:809-812.
24. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C. Modulation of steadystate kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther. 2002;72:584-594.
25. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 2001;11:293-298.
26. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol. 2002;53:526-534.
27. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002;71:297-303.
28. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18:1400-1404.
29. Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull. 2002;25:1356-1359.
30. Morita Y, Sakaeda T, Horinouchi M, Nakamura T, Kuroda K, Miki I. MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res. 2003;20:552-556.
31. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther. 2002;72:572-583.
32. Van Der Heiden IP, van der Heuvel MM, Wioemer E, Pieters R, Lindemans J, van der Anker J. MDR1 C3435T gene polymorphism does not correlate with P-gp expression and function in acute myeloid leukemia. Clin Pharmacol Ther. 2003;75:58.
33. Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics. 2002;12:451-457.
34. Oselin K, Gerloff T, Mrozikiewicz PM, Pahkla R, Roots I. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol. 2003;17:463-469.
35. Calado RT, Falcao RP, Garcia AB, Gabellini SM, Zago MA, Franco RF. Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. Haematologica. 2002;87:564-568.
36. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199.
37. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporine disposition in heart transplant recipients. Pharmacogenetics. 2003;13:89-95.
38. Min DI, Ellingrod VL. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit. 2002;24:400-404.
39. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 2003;43:555-564.
40. Von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem. 2001;47:1048-1052.
41. Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation. 2002;74:571-572.
42. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003;14:1889-1896.